First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors

Preclinical models suggest anticancer activity of IM156, a novel biguanide mitochondrial protein complex 1 inhibitor of oxidative phosphorylation (OXPHOS). This first-in-human dose-escalation study enrolled patients with refractory advanced solid tumors to determine the maximum tolerated dose (MTD)...

Descripción completa

Detalles Bibliográficos
Autores principales: Janku, Filip, Beom, Seung-Hoon, Moon, Yong Wha, Kim, Tae Won, Shin, Young G., Yim, Dong-Seok, Kim, Gun Min, Kim, Hyo Song, Kim, Sun Young, Cheong, Jae-Ho, Lee, Young Woo, Geiger, Barb, Yoo, Sanghee, Thurston, Archie, Welsch, Dean, Rudoltz, Marc S., Rha, Sun Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395488/
https://www.ncbi.nlm.nih.gov/pubmed/35802288
http://dx.doi.org/10.1007/s10637-022-01277-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395488/
https://www.ncbi.nlm.nih.gov/pubmed/35802288
http://dx.doi.org/10.1007/s10637-022-01277-9

Ejemplares similares